ANNOUNCING

The first bio-marker based trial for ME/CFS: Rapamycin pilot trial

Learn more.

Read our 2024 year-end newsletter

We are driving treatment-focused research for ME/CFS

Developing 1st-in-kind
Animal Models

Finding Key Treatable
Mechanisms

Defining Subsets

Our mouse models will change the face of ME/CFS research.

Animal models will spur discovery and attract pharmaceutical companies to study ME/CFS and similar diseases.

Model 1: PUBLICATION PENDING
Post-Exertional Malaise

Model 2:
Orthostatic Intolerance/POTS

Model 3:
Neuro-inflammation (Brain Fog)

The Simmaron Difference

We are uniting patients, doctors, and scientists in a quest for breakthroughs in ME/CFS & neuroimmune disease. Simmaron has a 40 year-old biobank, clinical expertise of Dr. Daniel Peterson, and excellence in collaborations. We are uniquely aimed at discovering diagnostics and treatments for ME/CFS.

Simmaron’s New Lab

Simmaron is starting animal research for drug discovery and molecular target identification. Diseases with mouse models have active drug pipelines, so our researchers are developing the first mouse models for ME/CFS.

Our Core Accomplishments

Over 30 peer-reviewed publications
on ME/CFS immunology, subsets, mechanisms and treatments.

Transformational collaborations with NIH Research Centers, CDC, Columbia University, Cornell University, Stanford University, University of Wisconsin Milwaukee, Milwaukee Institute for Drug Discovery, and Coppe Laboratories.

$4.5 million of funded research to date.

Sign up to receive updates